Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PYC Therapeutics Limited ( (AU:PYC) ) has provided an update.
PYC Therapeutics announced promising results from Phase 1/2 clinical trials of its drug candidate VP-001, aimed at treating Retinitis Pigmentosa type 11. The data, to be presented at upcoming international conferences, shows significant improvements in vision and quality of life for patients, with the drug being safe and well-tolerated. This positions PYC’s platform technology as a valuable tool in addressing blinding eye diseases, with plans to discuss a New Drug Application pathway with the FDA in June 2025.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases with no available options. The company has three clinical-stage drug development programs, including VP-001, which targets Retinitis Pigmentosa type 11, a blinding eye disease in children.
YTD Price Performance: -15.02%
Average Trading Volume: 539,256
Technical Sentiment Signal: Hold
Current Market Cap: A$650.3M
See more data about PYC stock on TipRanks’ Stock Analysis page.